Evidence map›Paper›PMID 32162820›Full record

ArticleThe oncologist2020

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

Daniel Y Wang, Jennifer L McQuade, Rajat R Rai, John J Park, Shilin Zhao, Fei Ye, Kathryn E Beckermann, Samuel M Rubinstein, Romany Johnpulle, Georgina V Long and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Aspirin and immunotherapy: a Faustian bargain?The Journal of clinical investigation · 2023
    Article
  17. Review
  18. Article
  19. Targeting of the tumor immune microenvironment by metformin.Journal of cell communication and signaling · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Daniel Y WangVanderbilt University, Nashville, Tennesee, USA.ORCID 0000-0002-3341-8652
Jennifer L McQuadeThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rajat R RaiMelanoma Institute Australia, Sydney, Australia.
John J ParkRoyal North Shore and Mater Hospitals, Sydney, Australia.
Shilin ZhaoVanderbilt University, Nashville, Tennesee, USA.
Fei YeVanderbilt University, Nashville, Tennesee, USA.
Kathryn E BeckermannVanderbilt University, Nashville, Tennesee, USA.
Samuel M RubinsteinVanderbilt University, Nashville, Tennesee, USA.
Romany JohnpulleVanderbilt University, Nashville, Tennesee, USA.
Georgina V LongMelanoma Institute Australia, Sydney, Australia.
Matteo S CarlinoMelanoma Institute Australia, Sydney, Australia.
Alexander M MenziesMelanoma Institute Australia, Sydney, Australia.
Michael A DaviesThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Douglas B JohnsonVanderbilt University, Nashville, Tennesee, USA.
Vanderbilt University · USMelanoma Institute Australia · AUThe University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USRoyal North Shore Hospital · AU

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Predicting and profiling long-term survival after immune checkpoint inhibitionK23CA204726 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B · 2016 to 2020
$756k
NCI NIH HHS K12 CA090625NCI NIH HHS K23 CA204726
6 · The paper itself

Abstract

Anti-programmed cell death protein-1 (anti-PD-1) therapy has greatly improved outcomes of patients with melanoma; however, many fail to respond. Although preclinical studies suggest a potentially synergistic relationship with anti-PD-1 therapy and certain concurrent medications, their clinical role remains unclear. Here, we retrospectively evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and other drugs in 330 patients with melanoma treated with anti-PD-1 therapy from four academic centers. In the cohort, 37% of patients used NSAIDs including aspirin (acetylsalicylic acid; ASA; 47%), cyclooxygenase (COX)-2 inhibitors (2%), and non-ASA/nonselective COX inhibitor NSAIDs (59%). The objective response rates (ORRs) were similar in patients with NSAID (43.4%) and no NSAID (41.3%) use with no significant difference in overall suvival (OS). There was a trend toward improved progression-free survival (PFS) in patients who took NSAIDs (median PFS: 8.5 vs. 5.2 months; p = .054). Most patients (71.3%) took NSAIDs once daily or as needed. Multivariate analysis did not reveal an association with NSAID use with ORR, PFS, or OS. Concurrent use of metformin or beta blockers did not affect ORR, PFS, or OS. Our study found no conclusive association of concurrent NSAID or other medication use with improved outcomes in patients with melanoma treated with anti-PD-1 therapy. Larger and more systematic analysis is required to confirm these findings.

Indexed as

MelanomaMetforminPharmaceutical PreparationsAnti-Inflammatory Agents, Non-SteroidalHumansRetrospective StudiesAnti-Inflammatory Agents, Non-SteroidalMetforminPharmaceutical Preparations

Identifiers

PMID32162820
PMCPMC7066699
OpenAlexW2990670839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.